Business
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19.
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"\n WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that based on molecular screening of 11,552 compounds comprising already FDA-approved drugs and those in clinical testing, Brilacidin, the Company’s defensin-mimetic drug candidate targeting COVID-19, was identified as one of the most promising potential inhibitors of SARS-CoV-2, the novel coronavirus responsible for COVID-19. The researchers who conducted the study concluded: “Clearly, these compounds should be further evaluated in experimental assays and clinical trials to confirm their actual activity against the disease.” The corresponding article, and a related image (Table 1), are provided below. Cavasotto C, et al (2020). “In Silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Quantum Mechanical Scoring.” ChemRxiv. Preprint. Posted April 12, 2020. https://chemrxiv.org/articles/In_silico_Drug_Repurposing_for_COVID-19_Targeting_SARS-CoV-2_Proteins_through_Docking_and_Quantum_Mechanical_Scoring/12110199 (pdf) Table 1 is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/ad9540a0-cf54-48c0-8d7f-38d90ec2eee0 Brilacidin has shown, in cellular assays, direct antiviral activity against SARS-CoV-2, and has been selected for further antiviral testing by researchers at the U.S. Regional Biocontainment Laboratory (RBL) who conducted these initial tests. A majority of drugs undergoing such testing at the RBL do not meet this threshold. The next phase of Brilacidin’s testing at the RBL is scheduled to commence shortly, with lab results to be shared upon completion. The Company also continues to engage in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials. Brilacidin and COVID-19Linked below is an overview document (a downloadable pdf) summarizing mechanism of action, pre/clinical data and academic literature supporting the development of Brilacidin as a potential novel COVID-19 therapeutic. This document builds on a previous version released at the beginning of March. “Mechanism of Action, Pre/Clinical Data and Academic Literature Sup...